Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.
Markman
Maurie
M
University of Texas MD Anderson Cancer Center, Houston, TX 77005, USA. mmarkman@mdanderson.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011446:Prospective Studies; D012107:Research Design; D043823:Taxoids / Q000494:pharmacology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D043823:Taxoids